PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

Abstract Background Scarce drug penetration in solid tumours is one of the possible causes of the limited efficacy of chemotherapy and is related to the altered tumour microenvironment. The abnormal tumour extracellular matrix (ECM) together with abnormal blood and lymphatic vessels, reactive stroma...

Full description

Bibliographic Details
Main Authors: Lavinia Morosi, Marina Meroni, Paolo Ubezio, Ilaria Fuso Nerini, Lucia Minoli, Luca Porcu, Nicolò Panini, Marika Colombo, Barbara Blouw, David W. Kang, Enrico Davoli, Massimo Zucchetti, Maurizio D’Incalci, Roberta Frapolli
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Mass spectrometry imaging
Drug distribution
Extracellular matrix
Hyaluronan
Solid tumours
Online Access:https://doi.org/10.1186/s13046-021-02070-x

Internet

https://doi.org/10.1186/s13046-021-02070-x

Similar Items